INO Prakiraan wutah bathi resik saben saham ing taun iki Inovio Pharma

INO (inovio.com) - tandha merek perusahaan

A prolonged depletion of cash reserves due to a lack of sales triggered a sharp spike in the annual EPS growth rate, where the figure remains around 50.40. Inovio Pharmaceuticals (INO) maintains a diversified drug portfolio that mitigates regulatory risks, while the creation of a DNA medicine base to combat cancer and viruses lays the foundation for future success, as evidenced by the volatile earnings trend on this chart.

INO Wutah bathi saben saham ing taun lumaku Inovio Pharma (04.07.2022 - 15.11.2026)

Rincian metrik komprehensif lan analitis Inovio (INO)

- nilai pasar lan prakiraan target analis:
Pambiji fundamental:INO - Inovio Pharma
Produk mawa merek inovio.com

The monopoly potential of Inovio Pharmaceuticals (INO) is based on a unique DNA vaccine delivery platform, where future pricing power depends directly on the commercialization of patents. By analyzing the year-over-year growth in earnings per share on GURU.Markets, an investor assesses the net income dynamics per share, which allows for the determination of the business's ability to offset inflationary pressure and confirm the fundamental value of the assets.